Literature DB >> 26221409

Statin use and risk of fracture: a meta-analysis.

Shaolin Jin1, Jianping Jiang1, Pengcheng Bai1, Mei Zhang1, Xujun Tong1, Hui Wang1, Youqun Lu1.   

Abstract

This meta-analysis investigates the associations of statins use and fracture risk. Two reviewers independently searched six databases including PubMed, Cochrane Library, Ovid, Embase, China National Knowledge Infrastructure (CNKI) and Wanfang databases. Studies retrieved from database searches were screened using our stringent inclusion and exclusion criteria. A sum of 17 studies, published between 2000 and 2014, were included in this meta-analysis. The results of this meta-analysis suggested that statins use was associated with a decreased risk of fracture (OR=0.80; 95% CI, 0.73-0.88; P < 0.00001). In the subgroup analysis by study design, statins was significantly associated with a decreased risk of fracture in both case-control studies (OR=0.67; 95% CI, 0.55-0.87; P < 0.0001) and cohort studies (OR=0.86; 95% CI, 0.77-0.97; P=0.02). In the female subgroup analysis, statins user showed decreased fracture risk (OR=0.76; 95% CI, 0.63-0.92; P=0.005). In the subgroup analysis by duration of follow-up, studies with both long and short duration of follow-up showed decreased risk of fracture (OR=0.67; 95% CI, 0.54-0.82; P=0.001 and OR=0.85; 95% CI, 0.74-0.96; P=0.01). Studies with large sample size and small sample size showed decreased risk of fracture (OR=0.85; 95% CI, 0.77-0.94; P=0.002 and OR=0.65; 95% CI, 0.54-0.78; P < 0.0001). In conclusion, this meta-analysis suggested a significant association between statins use and decreased fracture risk.

Entities:  

Keywords:  Statins; fracture; meta-analysis

Year:  2015        PMID: 26221409      PMCID: PMC4509354     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  23 in total

1.  Use of statins and risk of fractures.

Authors:  T P van Staa; S Wegman; F de Vries; B Leufkens; C Cooper
Journal:  JAMA       Date:  2001-04-11       Impact factor: 56.272

2.  Fluvastatin increases bone mineral density in postmenopausal women.

Authors:  Mituhiro Gotoh; Kenji Mizuno; Yoshiaki Ono; Michihiko Takahashi
Journal:  Fukushima J Med Sci       Date:  2011

3.  Simvastatin prevents skeletal metastasis of breast cancer by an antagonistic interplay between p53 and CD44.

Authors:  Chandi Charan Mandal; Nayana Ghosh-Choudhury; Toshi Yoneda; Goutam Ghosh Choudhury; Nandini Ghosh-Choudhury
Journal:  J Biol Chem       Date:  2011-01-03       Impact factor: 5.157

4.  Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women.

Authors:  K A Chan; S E Andrade; M Boles; D S Buist; G A Chase; J G Donahue; M J Goodman; J H Gurwitz; A Z LaCroix; R Platt
Journal:  Lancet       Date:  2000-06-24       Impact factor: 79.321

5.  Statin but not non-statin lipid-lowering drugs decrease fracture risk: a nation-wide case-control study.

Authors:  L Rejnmark; P Vestergaard; L Mosekilde
Journal:  Calcif Tissue Int       Date:  2006-07-24       Impact factor: 4.333

6.  Statin use, bone mineral density, and fracture risk: Geelong Osteoporosis Study.

Authors:  Julie A Pasco; Mark A Kotowicz; Margaret J Henry; Kerrie M Sanders; Geoffrey C Nicholson
Journal:  Arch Intern Med       Date:  2002-03-11

7.  Synergistic effect of statins and postmenopausal hormone therapy in the prevention of skeletal fractures in elderly women.

Authors:  Ludmila N Bakhireva; Michael R Shainline; Shelley Carter; Scott Robinson; Sarah J Beaton; James J Nawarskas; Margaret J Gunter
Journal:  Pharmacotherapy       Date:  2010-09       Impact factor: 4.705

8.  Statin use, clinical fracture, and bone density in postmenopausal women: results from the Women's Health Initiative Observational Study.

Authors:  Andrea Z LaCroix; Jane A Cauley; Mary Pettinger; Judith Hsia; Douglas C Bauer; Joan McGowan; Zhao Chen; Cora E Lewis; S Gene McNeeley; Maureen D Passaro; Rebecca D Jackson
Journal:  Ann Intern Med       Date:  2003-07-15       Impact factor: 25.391

9.  Plasma lipids and osteoporosis in postmenopausal women.

Authors:  Toru Yamaguchi; Toshitsugu Sugimoto; Shozo Yano; Mika Yamauchi; Hideaki Sowa; Qingxiang Chen; Kazuo Chihara
Journal:  Endocr J       Date:  2002-04       Impact factor: 2.349

10.  Association of statins and risk of fractures in a military health system: a propensity score-matched analysis.

Authors:  Ian M Ward; Eric M Mortensen; Daniel F Battafarano; Christopher R Frei; Ishak Mansi
Journal:  Ann Pharmacother       Date:  2014-07-28       Impact factor: 3.154

View more
  6 in total

Review 1.  Impediments to clinical application of exercise interventions in the treatment of cardiometabolic disease.

Authors:  N John Bosomworth
Journal:  Can Fam Physician       Date:  2019-03       Impact factor: 3.275

2. 

Authors:  N John Bosomworth
Journal:  Can Fam Physician       Date:  2019-03       Impact factor: 3.275

Review 3.  Efficacy of statins for osteoporosis: a systematic review and meta-analysis.

Authors:  T An; J Hao; S Sun; R Li; M Yang; G Cheng; M Zou
Journal:  Osteoporos Int       Date:  2016-11-25       Impact factor: 4.507

4.  Comparative efficacy and safety of statins for osteoporosis: a study protocol for a systematic review and network meta-analysis.

Authors:  Mengxin Xiong; Yaojun Xue; Wei Zhu; Ali Deng; Zhangkui Tan; Guangwen Zhou; Nan Xiang
Journal:  BMJ Open       Date:  2022-05-17       Impact factor: 3.006

5.  Case-control study examining the association between hip fracture risk and statins therapy in old people.

Authors:  Kao-Chi Cheng; Kuan-Fu Liao; Cheng-Li Lin; Cheng-Chieh Lin; Shih-Wei Lai
Journal:  Medicine (Baltimore)       Date:  2019-10       Impact factor: 1.817

6.  Statin Therapy and the Risk of Osteoporotic Fractures in Patients with Metabolic Syndrome: a Nested Case-Control Study.

Authors:  Kyoung Jin Kim; Jimi Choi; Ji Yoon Kim; Jae Hyun Bae; Kyeong Jin Kim; Hee Young Kim; Hye Jin Yoo; Ji A Seo; Nan Hee Kim; Kyung Mook Choi; Sei Hyun Baik; Sin Gon Kim; Nam Hoon Kim
Journal:  J Lipid Atheroscler       Date:  2021-07-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.